1. Incidence and prevalence of basal cell carcinoma (BCC) and locally advanced BCC (LABCC) in a large commercially insured population in the United States: A retrospective cohort study
- Author
-
Tom Karagiannis, Vivian Herrera, Renata Kisa, Caitriona O'Neill, Gary Goldenberg, Juzer Lotya, Jacqueline B. Palmer, and Daniel M. Siegel
- Subjects
Adult ,Male ,medicine.medical_specialty ,Pediatrics ,Skin Neoplasms ,Adolescent ,Databases, Factual ,Population ,Locally advanced ,Pharmacy ,Dermatology ,Disease ,Insurance Claim Review ,Young Adult ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,International Classification of Diseases ,Epidemiology ,medicine ,Humans ,Neoplasm Invasiveness ,Basal cell carcinoma ,Neoplasm Metastasis ,education ,Aged ,Retrospective Studies ,Aged, 80 and over ,education.field_of_study ,integumentary system ,business.industry ,Incidence ,Incidence (epidemiology) ,Retrospective cohort study ,Middle Aged ,medicine.disease ,United States ,Surgery ,Carcinoma, Basal Cell ,030220 oncology & carcinogenesis ,Female ,business - Abstract
Background Accurate evaluation of basal cell carcinoma (BCC) in the United States was not possible before the 2011 release of BCC-specific International Classification of Diseases, Ninth Revision, Clinical Modification codes. Objective We sought to describe BCC (including locally advanced BCC [LABCC]) incidence/prevalence and the characteristics of patients in a commercially insured US population. Methods This retrospective cohort study used Truven Health MarketScan database insurance claims. Patients, aged 18 years or older with 2 or more BCC claims at least 30 days apart from October 1, 2011, to September 30, 2012, were continuously enrolled in medical and pharmacy benefits for 12 months before and after the index claim. A specific algorithm was used to classify patients with LABCC. Results A total of 56,987 patients with BCC were identified (39,035 incident cases; 17,952 prevalent cases). Age-adjusted BCC incidence and prevalence were 226.09 and 342.64 per 100,000 persons, respectively. These values project to 542,782 patients (incidence) and 822,593 patients (prevalence) in the 2012 US population. LABCC was uncommon (471 cases identified; projected US incidence and prevalence: 4399 and 7940 patients, respectively). Limitations Use of medical claims data and retrospective analysis are limitations. Conclusion In a study designed to distinguish patients with LABCC from the general BCC population based on BCC-specific International Classification of Diseases, Ninth Revision, Clinical Modification codes, 0.8% were found to have LABCC, the majority having pre-existing disease.
- Published
- 2016